Join our daily newsletter At The Bell to receive exclusive market insights
Noxopharm has released data from its first set of pre-clinical studies and has confirmed idronoxil (IDX), used in the anti-cancer drug (Veyonda), activates the immune system.
The results confirm IDX activates cells, in both the innate and adaptive immune systems, which increases natural killer and T-helper cells.
These activated cells are then able to attack and clear harmful cells from the body.
While other drugs are limited in their effectiveness, Veyonda targets a wide range of cancerous cells and CEO Greg van Wyk believes it will be beneficial in the future.
“Veyonda appears to be a truly versatile drug candidate, with these immune-oncology effects having the potential to complement its radio-enhancing and chemo-enhancing functions across a broad range of cancer types,” he said.
While the global market for immune checkpoints was US$10.5 billion in 2017, it is projected to reach US$56 billion by 2025, based on what the rate of advancement is currently like.
The discovery of Veyonda is a potential means of overcoming the restricted benefit of current anti-cancer drugs with future studies done by Noxopharm focusing on how it works.
